Use of anticytokeratin monoclonal anti-idiotypic antibodies to improve tumor: nontumor ratio in experimental radioimmunolocalization.
1995 (English)In: Cancer Research, ISSN 0008-5472, E-ISSN 1538-7445, Vol. 55, no 23 Suppl, 5868s-5873s p.Article in journal (Refereed) Published
A syngeneic, high-affinity, anti-idiotypic monoclonal antibody (MAb; alpha TS1) raised against an anticytokeratin monoclonal antibody (TS1) was evaluated as a second antibody to promote the rapid clearance of radiolabeled TS1 from the blood during experimental radioimmunolocalization. By using a novel biosensor technology (BIAcore), association rate dissociation rate, and affinity constants between the idiotype and the anti-idiotype could be determined. The in vivo results in nude mice carrying HeLa Hep 2 tumors demonstrate the possibility of selectively regulating the amount of the idiotypic 125I-labeled circulating MAb by in vivo injection of this high-affinity, anti-idiotypic antibody. Injection of the anti-idiotype in a molar ratio of 0.75 to the idiotype cleared the blood pool from circulating radiolabeled idiotype within 24 h, with a concomitant rapid excretion of 125I in urine. The total amount of remaining radioactivity in the animals decreased to 15-20% during these 24 h, with the tumors still retaining 60-65% of their initial radioactivity. This approach, using syngeneic primary and secondary MAbs with minimized immunogenicity, significantly improves the tumor:nontumor ratio, thus improving efficiency in experimental radioimmunolocalization and radioimmunotherapy, leaving the endogenous antibody repertoire of the host unaffected.
Place, publisher, year, edition, pages
1995. Vol. 55, no 23 Suppl, 5868s-5873s p.
IdentifiersURN: urn:nbn:se:umu:diva-41918PubMedID: 7493362OAI: oai:DiVA.org:umu-41918DiVA: diva2:408125